189 related articles for article (PubMed ID: 16498671)
1. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Tong FK; Chow S; Hedley D
Cytometry B Clin Cytom; 2006 May; 70(3):107-14. PubMed ID: 16498671
[TBL] [Abstract][Full Text] [Related]
2. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations.
Chow S; Hedley D; Grom P; Magari R; Jacobberger JW; Shankey TV
Cytometry A; 2005 Sep; 67(1):4-17. PubMed ID: 16080188
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
[TBL] [Abstract][Full Text] [Related]
5. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
[TBL] [Abstract][Full Text] [Related]
6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
7. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry.
Bardet V; Tamburini J; Ifrah N; Dreyfus F; Mayeux P; Bouscary D; Lacombe C
Haematologica; 2006 Jun; 91(6):757-64. PubMed ID: 16769577
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
Hedley DW; Chow S; Goolsby C; Shankey TV
Toxicol Pathol; 2008 Jan; 36(1):133-9. PubMed ID: 18337231
[TBL] [Abstract][Full Text] [Related]
9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
[TBL] [Abstract][Full Text] [Related]
10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
11. DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis.
Inokuchi K; Miyake K; Takahashi H; Dan K; Nomura T
J Clin Invest; 1996 Feb; 97(3):852-7. PubMed ID: 8609244
[TBL] [Abstract][Full Text] [Related]
12. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
13. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
[TBL] [Abstract][Full Text] [Related]
14. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
Xie W; Wang X; Du W; Liu W; Qin X; Huang S
Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
[TBL] [Abstract][Full Text] [Related]
15. Immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.
Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Zheng Y; Qian L; Yang T; Yang C; Feng B
Chin Med J (Engl); 1998 Jan; 111(1):28-31. PubMed ID: 10322648
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
[TBL] [Abstract][Full Text] [Related]
17. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
[TBL] [Abstract][Full Text] [Related]
18. Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34.
Pallis M; Syan J; Russell NH
Cytometry; 1999 Dec; 37(4):308-13. PubMed ID: 10547616
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0).
Kotylo PK; Seo IS; Smith FO; Heerema NA; Fineberg NS; Miller K; Greene ME; Chou P; Orazi A
Am J Clin Pathol; 2000 Feb; 113(2):193-200. PubMed ID: 10664621
[TBL] [Abstract][Full Text] [Related]
20. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
Lee M
Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
